TickerFacts.

Company research / CSTL

Castle Biosciences Inc (CSTL)

Build a valuation ↗↓ Download CSV

SEC name CASTLE BIOSCIENCES INC · CIK 0001447362 · Nasdaq · Services-Medical Laboratories

  • Sector Services
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Castle Biosciences Inc reported revenue of $344.23M. Revenue grew 3.7% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $357.28M.

Key ratios (year ended 2025-12-31)

79.4%
Gross margin (computed)
-12.4%
Operating margin
-7.0%
Net margin
-5.1%
Return on year-end equity
3.7%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-21

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$357.28M$344.23M$332.07M$219.79M$137.04M$94.08M$62.65M$51.87M$22.79M
Cost of Revenue$81.25M$71.03M$60.20M$44.98M$32.01M$15.82M$9.69M$7.31M$5.30M
Gross Profit$276.03M$273.20M$271.86M$174.81M$105.03M$78.26M$52.96M$44.55M$17.49M
R&D Expense$55.45M$51.85M$52.04M$53.62M$44.90M$29.65M$13.26M$7.38M$4.85M
Operating Income-$32.11M-$42.81M$8.67M-$67.98M-$72.86M-$40.08M-$6.54M$7.33M-$3.84M
Depreciation & Amortization$15.59M$40.77M$16.00M$12.33M$10.54M$3.41M$472.0Kn/an/a
EBITDA-$16.52M-$2.04M$24.67M-$55.65M-$62.31M-$36.67M-$6.07Mn/an/a
Net Income-$19.41M-$24.16M$18.25M-$57.47M-$67.14M-$31.29M-$10.28M$5.28M-$6.37M
EPS (Diluted)n/a-$0.83$0.62-$2.14-$2.58-$1.24-$0.54-$0.21-$5.33
Total Assets$561.18M$578.56M$531.24M$453.34M$447.33M$462.57M$439.33M$119.75M$22.41M
Total Liabilities$91.15M$107.68M$75.40M$62.07M$48.18M$50.83M$23.64M$34.63M$32.48M
Long-Term Debt$10.07M$10.06M$10.02M$0n/an/an/a$26.69Mn/a
Shareholders' Equity$470.03M$470.87M$455.83M$391.27M$399.15M$411.74M$415.69M$85.11M-$56.57M
Cash & Equivalents$62.12M$116.73M$119.71M$98.84M$122.95M$329.63M$409.85M$98.84M$4.48M
Operating Cash Flow$42.63M$64.35M$64.87M-$5.63M-$41.66M-$18.98M$9.87M$7.01M-$12.29M
Capital Expenditures$43.12M$36.02M$28.33M$13.62M$5.63M$3.48M$4.75M$937.0K$277.0K
Free Cash Flow-$489.0K$28.33M$36.54M-$19.25M-$47.29M-$22.47M$5.11M$6.08M-$12.57M
Shares Outstanding30.51M29.69M28.48M27.41M26.55M25.38M24.81M17.13M1.92M
Dividends Per Sharen/a$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Weighted Average Diluted Sharesn/a28.99M29.25M26.80M26.05M25.14M18.93M8.66M1.91M
EPS (Basic)n/a-$0.83$0.66-$2.14-$2.58-$1.24-$0.54$0.35-$5.33

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView